{"nctId":"NCT01227421","briefTitle":"Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","startDateStruct":{"date":"2010-12"},"conditions":["Influenza"],"count":624,"armGroups":[{"label":"Nitazoxanide, Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitazoxanide"]},{"label":"Nitazoxanide, Nitazoxanide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitazoxanide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Nitazoxanide","otherNames":["Alinia, NTZ"]},{"name":"Nitazoxanide","otherNames":["Alinia, NTZ"]},{"name":"Placebo","otherNames":["Sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA\n\n* age 12 to 65 years\n* Presence of clinical signs, respiratory symptoms and constitutional symptoms compatible with influenza infection:\n\n  1. fever,\n  2. at least one of the following respiratory symptoms: cough, sore throat, nasal discharge, nasal congestion, sneezing.\n  3. At least one of the following constitutional symptoms: headache, myalgia, seats, chills, fatigue of any severity (mild, moderate, severe)\n* Confirmation of Influenza A or B infection in the local community\n* Onset of illness no more than 48 hours before presentation. Time of onset of illness is defined as either the earlier of (1) the time when the temperature was first measured as elevated, or (2) the time when the patient experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.\n* willing and able to comply with protocol requirements and provide informed consent\n\nEXCLUSION CRITERIA:\n\n* severity of illness requiring or anticipated to require in-hospital care\n* High risk of complications from influenza as follows:\n\n  1. persons with asthma or other chronic pulmonary diseases\n  2. persons with hemodynamically significant cardiac disease\n  3. persons who have immunosuppressive disorders or receiving immunosuppressive therapy\n  4. persons infected with Human Immunodeficiency Virus (HIV)\n  5. persons with sickle cell anemia or other hemoglobinopathies\n  6. persons with diseases requiring long-term aspirin therapy\n  7. persons with chronic renal dysfunction\n  8. persons with liver disorders\n  9. Persons with cancer\n  10. Persons with chronic metabolic disease such as diabetes and inherited mitochondrial disorders\n  11. Persons with neuromuscular disorders, seizure disorders, or cognitive dysfunction\n  12. Residents of any age of nursing homes or long-term institutions.\n* Females of child bearing age who are pregnant, breastfeeding or sexually active without birth control\n* vaccination for influenza or H1N1 (Swine Flu) on or after August 1, 2010\n* treatment with antiviral medication such as oseltamivir, zanamivir, amantadine, or rimantadine within 30 days of screening.\n* Prior treatment with nitazoxanide within 30 days prior to screening.\n* subjects with active respiratory allergies or expected to require anti-allergy medications during the study period.\n* known sensitivity to nitazoxanide\n* subjects unable to take oral medication\n* subjects with chronic kidney or liver disease\n* Presence of any other pre-existing chronic infection that is undergoing or requiring medical therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects","description":"The primary efficacy analysis for this study was to demonstrate the efficacy of Nitazoxanide (NTZ) administered as 300 mg b.i.d. for 5 days or 600 mg b.i.d. for 5 days in reducing the time to resolution of all clinical symptoms of influenza in patients with laboratory confirmed influenza infection","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.1","spread":null},{"groupId":"OG001","value":"116.7","spread":null},{"groupId":"OG002","value":"95.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Resolution of Each Individual Symptom of Influenza as Reported by the Subjects","description":"Time in hours (Median and Interquartile range)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"104","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change (Standard Deviation)in 50% Tissue Culture Infective Dose (TCID50) Viral Titer From Baseline","description":"Change in viral titer presented as logarithm with base 10 (log10) 50% Tissue Culture Infective Dose (TCID50)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"1.4"},{"groupId":"OG001","value":"-0.03","spread":"1.7"},{"groupId":"OG002","value":"-1.11","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"1.8"},{"groupId":"OG001","value":"-1.21","spread":"2.2"},{"groupId":"OG002","value":"-1.84","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"1.9"},{"groupId":"OG001","value":"-1.65","spread":"1.9"},{"groupId":"OG002","value":"-2.58","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.46","spread":"1.8"},{"groupId":"OG001","value":"-2.41","spread":"1.8"},{"groupId":"OG002","value":"-2.55","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.82","spread":"1.6"},{"groupId":"OG001","value":"-2.79","spread":"1.8"},{"groupId":"OG002","value":"-3.01","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Mean Change in RT-PCR (Reverse Transcription Polymerase Chain Reaction) Viral Titer From Baseline","description":"Change in viral titer logarithm with base 10 (log10) Ribonucleic Acid (RNA)copies","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"1.4"},{"groupId":"OG001","value":"-0.22","spread":"1.7"},{"groupId":"OG002","value":"-0.73","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"1.4"},{"groupId":"OG001","value":"-0.92","spread":"2.0"},{"groupId":"OG002","value":"-1.64","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"1.5"},{"groupId":"OG001","value":"-1.63","spread":"1.8"},{"groupId":"OG002","value":"-2.21","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.42","spread":"1.5"},{"groupId":"OG001","value":"-2.49","spread":"1.7"},{"groupId":"OG002","value":"-2.44","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.97","spread":"1.3"},{"groupId":"OG001","value":"-2.82","spread":"1.6"},{"groupId":"OG002","value":"-3.08","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Time to Cessation of Viral Shedding Measure by 50% Tissue Culture Infective Dose (TCID50)","description":"Median time in hours","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":null},{"groupId":"OG001","value":"91.3","spread":null},{"groupId":"OG002","value":"71.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Return to Normal Daily Activities","description":"Time in hours as reported by patient","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"82.1","spread":null},{"groupId":"OG002","value":"84.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptom Severity Score Hours","description":"Sum of the symptom severity score hours from first dose to resolution of symptoms. Patients rated each symptom's severity on a score from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe). Total symptom severity score hours were calculated by multiplying the sum of the severity scores by duration of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1035.1","spread":"765"},{"groupId":"OG001","value":"1220.9","spread":"592"},{"groupId":"OG002","value":"1125.2","spread":"681"}]}]}]},{"type":"SECONDARY","title":"Time Loss From Work","description":"Time loss from work","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Complications of Influenza","description":"Proportion of patients with a complication of influenza during the course of the study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Influenza Antibody Response Titer Change: Influenza A 2009 H1N1","description":"change in influenza antibody titer for Influenza A 2009 H1N1","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Influenza Antibody Response: Influenza A H3N2","description":"Change in antibody titer for Influenza A H3N2","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Influenza Antibody Response: Influenza B","description":"Change in antibody titer for Influenza B","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A 2009 H1N1","description":"Proportion of patients seroprotected or seroconverted at day 28","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A H3N2","description":"Proportion of patients seroprotected and seroconverted at day 28","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Influenza Antibody Response: Seroprotection and Seroconversion for Influenza B","description":"Proportion of patients seroprotected and seroconverted at day 28","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":201},"commonTop":["Mild Diarrhea","Chromaturia"]}}}